HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Hepsera Clears FDA; Hepatitis B Therapy Will Cost $440 Per Month

Executive Summary

Gilead is launching the hepatitis B agent Hepsera (adefovir) at a wholesale acquisition cost of $440 per month
Advertisement

Related Content

Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.
Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.
Gilead Viread Virology Data Will Distinguish HIV Drug In Physician Promotions
Gilead Adefovir Approval Awaits "Unequivocal" Evidence Of Efficacy At 60 mg
Advertisement
UsernamePublicRestriction

Register

PS040503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel